These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17131467)

  • 1. Insulin resistance and hepatitis C.
    Romero-Gómez M
    World J Gastroenterol; 2006 Nov; 12(44):7075-80. PubMed ID: 17131467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
    Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
    Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
    Sanyal AJ
    Liver Int; 2011 Jan; 31 Suppl 1():23-8. PubMed ID: 21205134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
    Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C and insulin resistance: steatosis, fibrosis and non-response.
    Romero-Gómez M
    Rev Esp Enferm Dig; 2006 Aug; 98(8):605-15. PubMed ID: 17048997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
    Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
    Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: some issues.
    Wu KT; Yang JF; Chuang WL; Yu ML
    J Hepatol; 2010 Feb; 52(2):305; author reply 305-6. PubMed ID: 20006403
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
    Fattovich G; Baroni GS; Pasino M; Pierantonelli I; Covolo L; Ieluzzi D; Passigato N; Tonon A; Faraci MG; Guido M; Negro F
    Dig Liver Dis; 2012 May; 44(5):419-25. PubMed ID: 22277808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
    Conjeevaram HS; Wahed AS; Afdhal N; Howell CD; Everhart JE; Hoofnagle JH;
    Gastroenterology; 2011 Feb; 140(2):469-77. PubMed ID: 21070775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
    Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
    Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
    Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon and ribavirin for hepatitis C.
    Assy N; Embon O
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17380576
    [No Abstract]   [Full Text] [Related]  

  • 17. [Insulin resistance in chronic hepatitits C].
    Parise ER; Oliveira AC
    Arq Gastroenterol; 2007; 44(2):178-84. PubMed ID: 17962866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.